Search

Displaying results 1451 - 1460 of 4575 in total
  1. Drug

    Rifabutin

    go.drugbank.com/drugs/DB00615
    ApprovedInvestigational

    A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.

  2. Drug

    Dexibuprofen

    go.drugbank.com/drugs/DB09213
    ApprovedWithdrawn

    Dexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties. It is proposed to be more pharmacologically ...

  3. Drug

    Clobetasol propionate

    go.drugbank.com/drugs/DB01013
    ApprovedInvestigational

    Clobetasol propionate is a prednisolone derivative with higher specificity for glucocorticoid receptors than mineralocorticoid receptors. It has demonstrated superior activity compared to fluocinonide and was first described in the liter...

    Mixtures: Vixa Skineal
  4. Drug

    Methylchloroisothiazolinone

    go.drugbank.com/drugs/DB14197
    Approved

    Methylchloroisothiazolinone (MCI) is an isothiazolinone commonly used as a preservative with antibacterial and antifungal properties. It is found within many commercially available cosmetics, lotions, and makeup removers. It is also a kn...

  5. Drug

    Thiohexam

    go.drugbank.com/drugs/DB14200
    Approved

    Thiohexam is a rubber cure accelerator. It is also a known allergen and dermatological sensitizer. Sensitivity to Thiohexam may be identified with a clinical patch test.

  6. Drug

    ISF402

    go.drugbank.com/drugs/DB06315
    Experimental

    ISF402 is an investigational peptide tetramer which helps dispersal of insulin via zinc chelation, therefore allowing insulin hexamers to break free.

  7. Drug

    Levcromakalim

    go.drugbank.com/drugs/DB21154
    Investigational

    Levcromakalim is under investigation in clinical trial NCT04853797 (Effect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura (ILIM)).

  8. Drug

    Enasidenib

    go.drugbank.com/drugs/DB13874
    ApprovedInvestigational

    First developed by Agios Pharmaceuticals and licensed to Celgene, enasidenib was approved by U.S. Food and Drug Administration on August 1, 2017. … Patients eligible for this treatment are selected by testing the presence of IDH2 mutations in the blood or bone marrow.

  9. Drug

    Efonidipine

    go.drugbank.com/drugs/DB09235
    Investigational

    Efonidipine is a calcium channel blocker of the _dihydropyridine class_, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, _Landel_.

  10. Drug

    Flucloxacillin

    go.drugbank.com/drugs/DB00301
    ApprovedInvestigationalWithdrawn

    Antibiotic analog of cloxacillin.